Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (NYSE: DGX) is a medical laboratories company focused on diagnostic testing and diagnostic information services, and its news flow reflects its role across the healthcare ecosystem. The company regularly issues updates on its financial reporting schedule, including announcements about quarterly and full-year results and related conference calls, which are of interest to investors tracking DGX stock and performance trends.
News about Quest Diagnostics also covers participation in major healthcare and investor conferences. For example, the company has announced presentations at events such as the J.P. Morgan Healthcare Conference and Citi’s Global Healthcare Conference, where its leadership discusses strategy, performance and market developments. These appearances provide insight into how the company views its position in the diagnostic testing and information services market.
Quest Diagnostics’ news includes information on collaborations and joint ventures that expand access to laboratory services. Announcements have highlighted a laboratory services joint venture with Corewell Health in Michigan, as well as the ongoing role of Sonora Quest Laboratories, an Arizona-based joint venture between Banner Health and Quest Diagnostics. Such items help readers understand how Quest Diagnostics partners with health systems to deliver regional laboratory services and hospital lab management solutions.
In addition, Quest Diagnostics reports on developments in specialized diagnostics through subsidiaries and collaborations. News has featured Haystack MRD, a minimal residual disease test developed by Haystack Oncology, a wholly owned subsidiary of Quest Diagnostics, including data presentations at scientific meetings and clinical research collaborations. Other coverage has described a strategic collaboration with Octave Bioscience to expand access to the Octave Multiple Sclerosis Disease Activity Test through Quest’s specimen-collection network.
Visitors to the DGX news page can review these types of updates to follow financial communications, strategic partnerships, scientific data presentations and corporate announcements that shape Quest Diagnostics’ activities in the medical laboratories sector.
On November 4, 2022, Quest Diagnostics (NYSE: DGX) launched three innovative fitness panels on questhealth.com. These panels are tailored for athletes at all levels and assess overall fitness by analyzing endurance, nutrition, hydration, energy, and hormone levels. The panels include the Essentials, Nutrition, and Elite Profiles, priced between $269 and $559. Results are available electronically within 7-14 days and may be covered by HSA/FSA. The initiative aims to empower athletes with actionable insights for enhanced performance and injury prevention.
Quest Diagnostics (NYSE: DGX) has been recognized in Fast Company's annual Brands That Matter list for its impactful Quest for Health Equity initiative. The initiative represents over $100 million allocated to reduce health disparities in underserved communities, addressing critical issues like heart disease and diabetes. The Fast Company list honors brands that create cultural impact and engagement, with Quest being acknowledged for its relevancy and emotional connection with the public. This highlights Quest's commitment to promoting health equity and community well-being.
Quest Diagnostics (NYSE: DGX) has announced the appointment of Jim Davis as CEO and President, succeeding Steve Rusckowski, who remains as Chairman until March 2023. This transition, initiated on February 3, 2022, aims to strengthen leadership following Rusckowski's decade-long service. Davis, who joined Quest in 2013, has led the company’s response to the COVID-19 pandemic. He emphasized a focus on growth, operational excellence, and advancing diagnostics to improve health outcomes.
Quest Diagnostics partners with Saint Louis University to launch an accelerated bachelor's degree program in medical laboratory science. This 16-month program aims to address the critical shortage of medical laboratory scientists, essential for performing diagnostic tests that inform patient diagnoses and treatments. Currently, the U.S. lacks enough graduates to meet the projected demand of 12,600 new jobs in this field by 2030. The collaboration ensures hands-on training and a potential 100% job placement rate for graduates, highlighting the urgent need for skilled professionals.
Bread of Life, Inc. has launched the Healthy Houston Collective program with the Quest Diagnostics Foundation, targeting healthcare disparities in Houston. The initiative aims to support over 9,000 individuals in underserved communities, backed by a $3.8 million grant. Key program areas include the Community Care Program, health careers training, and collaborations with Federally Qualified Health Centers. The goal is to provide accessible healthcare services, education, and job opportunities while battling health inequities in the region.
Quest Diagnostics (NYSE: DGX) has partnered with Sesame Workshop to launch a nationwide initiative aimed at reducing health inequities among young children, particularly in low-income and marginalized communities. This program seeks to address the impact of the pandemic on children's healthcare by providing English and Spanish resources to support parents and healthcare providers. Notably, research indicates that children from lower-income households are more likely to miss routine health check-ups. The initiative promotes a 'healthy team' approach, fostering partnerships that empower families and enhance children's overall well-being.
Quest Diagnostics (DGX) reported third quarter revenues of $2.49 billion, down 10.4% from 2021. Reported diluted earnings per share (EPS) were $2.17, a decline of 46.0%, while adjusted diluted EPS was $2.36, down 40.4%. Base business revenues increased by 5.1% to $2.17 billion. The company raised full-year 2022 EPS guidance to a range of $8.52 to $8.72 and adjusted EPS to $9.75 to $9.95. CEO-elect Jim Davis emphasized growth in the base business despite challenges, including Hurricane Ian.
Decode Health announced a new collaboration phase with Quest Diagnostics (NYSE: DGX) to advance drug and diagnostics research in metabolic disease and autoimmune neurology. This phase will focus on RNA sequencing and specimen collection through Quest's extensive network, including 2,100 patient service centers. The partnership aims to enhance biomarker discovery, crucial for developing novel diagnostic tests and drug therapies. The initial targets include multiple sclerosis and non-alcoholic fatty liver disease, with plans for future expansion into other clinical areas.
Quest Diagnostics (NYSE: DGX) launched a new campaign, "Put Your ___ To The Test," encouraging consumers to take charge of their health with over 50 lab tests available online without requiring a doctor's visit. This campaign, developed by R/GA, highlights the ease of accessing high-quality tests. Quest aims to educate consumers on the value of lab testing, offering categories such as general wellness and sexual health. The campaign will utilize digital media and TV advertisements throughout 2023, aiming to transform Quest into an emerging lifestyle brand.
Quest Diagnostics (NYSE: DGX) announced significant leadership changes to support its strategy for growth and operational excellence. CEO-Elect Jim Davis appointed Karthik Kuppusamy as Senior VP of Clinical Solutions, Mark Gardner as Senior VP of Molecular Genomics and Oncology, and Kristin Wallace as Senior VP of Compliance. These seasoned executives are expected to bolster the company’s innovation and compliance leadership post-pandemic. The appointments reflect Quest's commitment to enhancing its market position in diagnostic services.